18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations |
| |
Authors: | Alexandre Cochet Inna Dygai-Cochet Jean-Marc Riedinger Olivier Humbert Alina Berriolo-Riedinger Michel Toubeau Séverine Guiu Charles Coutant Bruno Coudert Pierre Fumoleau François Brunotte |
| |
Institution: | 1. Department of Nuclear Medicine, Centre Georges-Fran?ois Leclerc, 1 rue Professeur Marion, 21079, Dijon Cedex, France 2. Le2i UMR CNRS 6306, Dijon, France 3. MRI and Spectroscopy Unit, CHU Dijon, Dijon, France 4. Department of Oncology, Centre Georges-Fran?ois Leclerc, Dijon, France 5. Department of Surgery, Centre Georges-Fran?ois Leclerc, Dijon, France
|
| |
Abstract: | Purpose The objective of this study was to assess the impact on management and the prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for initial staging of newly diagnosed large breast cancer (BC) when compared with conventional staging. Methods We prospectively included 142 patients with newly diagnosed BC and at least grade T2 tumour. All patients were evaluated with complete conventional imaging (CI) procedures (mammogram and/or breast ultrasound, bone scan, abdominal ultrasound and/or CT, X-rays and/or CT of the chest), followed by FDG PET/CT exploration, prior to treatment. The treatment plan based on CI staging was compared with that based on PET/CT findings. CI and PET/CT findings were confirmed by imaging and clinical follow-up and/or pathology when assessable. Progression-free survival (PFS) was analysed using the Cox proportional hazards regression model. Results According to CI staging, 79 patients (56 %) were stage II, 46 (32 %) stage III and 17 (12 %) stage IV (distant metastases). Of the patients, 30 (21 %) were upstaged by PET/CT, including 12 (8 %) from stage II or III to stage IV. On the other hand, 23 patients (16 %) were downstaged by PET/CT, including 4 (3 %) from stage IV to stage II or III. PET/CT had a high or medium impact on management planning for 18 patients (13 %). Median follow-up was 30 months (range 9–59 months); 37 patients (26 %) experienced recurrence or progression of disease during follow-up and 17 patients (12 %) died. The Cox model indicated that CI staging was significantly associated with PFS (p?=?0.01), but PET/CT staging provided stronger prognostic stratification (p?<?0.0001). Moreover, Cox regression multivariate analysis showed that only PET/CT staging remained associated with PFS (p?<?0.0001). Conclusion FDG PET/CT provides staging information that more accurately stratifies prognostic risk in newly diagnosed large BC when compared with conventional explorations alone. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|